IRNAOMICS(2257.HK):A DIFFERENTIATED BIOTECH COMPANY IN RNAI THERAPEUTICS
招银国际Jan 12 19:21
CICC: Maintains Shengnuo Pharmaceutical-B (02257) “Outperforms the Industry” rating and lowers the target price to HK$72.1
Zhitong FinanceSep 1, 2023 09:46
Nomura Adjusts Sirnaomics' Price Target to HK$67.07 From HK$70.07, Keeps at Buy
MT NewswiresJun 20, 2023 21:02
Nomura Adjusts Sirnaomics' Price Target to HK$70.07 From HK$107.14, Keeps at Buy
MT NewswiresMar 30, 2023 17:58
Shengnuo Pharmaceutical-B (2257.HK): Core products show skin cancer treatment potential and continue to improve the layout of indications
平安證券Aug 31, 2022 00:00
Shengnuo Pharmaceutical-B (02257.HK): A clinical-stage biopharmaceutical company exploring RNA therapy
中金公司Aug 2, 2022 00:00
Shengnuo Pharmaceutical-B (2257.HK): Small Nucleic Acid Track Pioneers Differentiate the Field of Oncology and Fibrosis
平安證券Jun 12, 2022 00:00
Shengnuo Pharmaceutical-B (2257.HK): IPO Purchase Guide
國元國際Dec 20, 2021 00:00
IPO News: Shengnuo Pharmaceutical-B (2257.HK)
致富證券Dec 20, 2021 00:00
No Data
No Data